A type of Streptococcus salivarius MG-T313 for improving oral health and its uses
By screening and developing Streptococcus salivarius MG-T313, the problems of insufficient bacterial resources and insufficient colonization in existing technologies have been solved, achieving broad-spectrum antibacterial activity and strong adhesion and colonization, effectively improving oral health.
Patent Information
- Application Number
- CN202611223956.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-08-13
- Publication Date
- 2026-11-10
AI Technical Summary
Existing technologies related to Streptococcus salivarius suffer from problems such as a lack of bacterial strains, a narrow spectrum of antibacterial activity, insufficient colonization capacity, low density of live bacteria during fermentation, and poor freeze-drying performance, making it difficult to safely and sustainably maintain oral health without disrupting the normal oral microecology.
A strain of Streptococcus salivarius MG-T313 (CGMCC No. 38628) is provided. This strain is safe to obtain, has broad-spectrum antibacterial ability, can effectively inhibit Gram-positive and Gram-negative periodontal pathogens and fungi, and has strong adhesion and colonization ability and high self-aggregation rate. It can be used to prepare bacterial agents for oral health improvement products.
MG-T313 has a significant antibacterial effect against a variety of oral pathogens. It can effectively destroy cariogenic plaque biofilm, reduce the risk of demineralization, improve adhesion and colonization ability, and prolong the duration of action. It is suitable for caries prevention and treatment, periodontal inflammation control and halitosis improvement.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
Technical Field
[0001] This invention relates to the field of microbiology, and in particular to a salivary streptococcus MG-T313 that improves oral health and its uses. Background Technology
[0002] The oral cavity is a crucial site for the aggregation of human microorganisms, with over 700 species identified. In a healthy state, the microbiome and host maintain a dynamic balance. However, poor oral hygiene, dietary imbalances, weakened immunity, or prolonged antibiotic use can lead to microecological imbalances, allowing pathogenic bacteria to become dominant and causing various diseases. Among these, acid-producing and acid-resistant bacteria such as *Streptococcus mutans* lower plaque pH and cause enamel demineralization, resulting in tooth decay. Gram-negative anaerobic bacteria such as *Porphyromonas gingivalis* and *Fusobacterium nucleatum* cause gingivitis, periodontitis, and alveolar bone resorption, and decompose sulfur-containing amino acids to produce volatile sulfur compounds (VSCs), leading to halitosis. *Streptococcus pyogenes* is a common pathogen in pharyngitis and tonsillitis. Over-colonization of *Candida albicans* can cause oral candidiasis. Research also suggests that oral pathogens are associated with systemic diseases such as atherosclerosis, diabetes, and adverse pregnancy outcomes.
[0003] Existing control methods mainly include: mechanical cleaning is insufficient to remove plaque from hidden areas such as the subgingival and lingual dorsum, and plaque reforms within 24-48 hours; chemical antibacterial agents such as chlorhexidine, cetylpyridinium chloride, and triclosan lack selectivity, killing both pathogenic and beneficial bacteria, exacerbating microecological imbalance with long-term use, and causing tooth discoloration, taste changes, and mucosal dryness and pain, with rapid rebound of pathogens after discontinuation; antibiotics face the challenges of drug resistance and bacterial dysbiosis, making them unsuitable for long-term prevention; functional components such as fluoride, xylitol, and CPP-ACP have single targets and limited effectiveness against mature pathogenic biofilms. All of the above "killing-oriented" strategies are insufficient to rebuild a healthy microbial community structure.
[0004] Oral probiotics based on "bacterial replacement therapy" have therefore attracted attention. They inhibit pathogenic bacteria through multiple mechanisms, including competitive adhesion and occupation, competition for nutrients, secretion of bacteriocins, inhibition of biofilm formation, and regulation of local immunity. However, early studies mostly used Lactobacillus and Bifidobacterium derived from the gut or fermented foods. These are not native to the oral cavity and are difficult to colonize in the saliva-washing environment. In addition, some strains have a strong acid-producing capacity, which poses a risk of promoting demineralization.
[0005] Streptococcus salivarius is a dominant native commensal bacterium of the oral cavity and upper respiratory tract. It colonizes the dorsum of the tongue and oral mucosa early in life, and its safety is based on long-term coexistence with humans. Some strains can produce salivaricin-like antimicrobial peptides, exhibiting strong adhesion and site-occupancy capabilities. Furthermore, it can increase plaque pH, interfere with extracellular polysaccharide-mediated biofilm formation, and downregulate the expression of inflammatory factors such as IL-6, IL-8, and TNF-α through urease or arginine deiminase systems. Currently, strains such as K12 and M18 are used in products such as lozenges and mouthwashes.
[0006] However, existing technologies related to *Streptococcus salivans* still have significant shortcomings: First, there is a scarcity of available bacterial strains, and most strains have a narrow antibacterial spectrum, effective only against *Streptococcus pyogenes* or *Streptococcus mutans*, with weak inhibitory effects on periodontal pathogens and *Candida albicans*, making it difficult to simultaneously address multiple needs such as caries prevention, anti-inflammation, and halitosis elimination; Second, due to the effects of saliva rinsing, swallowing clearance, lysozyme and sIgA action, and resistance to colonization by protozoa, the adhesion and colonization abilities of strains are insufficient, and they are eliminated upon discontinuation, lacking a sustained effect; Third, some strains have low viable cell density during fermentation and poor freeze-drying survival rate, resulting in high production costs.
[0007] Therefore, there is an urgent need in this field to screen for a safe-sourced, broad-spectrum, highly colonizing, and excellent fermentation and freeze-drying Streptococcus salivarius strain, and to develop corresponding stabilization compositions to safely and sustainably maintain oral health without disrupting the normal oral microecology. Summary of the Invention
[0008] In view of the shortcomings of the prior art described above, the purpose of this invention is to provide a salicylic streptococcus MG-T313 that improves oral health and solves the problems in the prior art.
[0009] To achieve the above and other related objectives, this invention provides a Streptococcus salivarius MG-T313, with accession number CGMCC No. 38628, accession date of 2026-05-11, deposited at the China General Microbiological Culture Collection Center (CGMCC), Institute of Microbiology, Chinese Academy of Sciences, Beijing.
[0010] Preferably, the *Streptococcus salivarius* MG-T313 comprises a DNA fragment with a nucleotide sequence as shown in SEQ ID No. 1.
[0011] The present invention also provides a bacterial agent containing the aforementioned Streptococcus salivarius MG-T313.
[0012] The present invention also provides the use of the aforementioned Streptococcus salivarius MG-T313 or the aforementioned bacterial agent in the preparation of oral health improvement products, anti-allergy products or anti-inflammatory products.
[0013] As described above, the present invention provides a salivary streptococcus MG-T313 for improving oral health and its uses, which have the following beneficial effects:
[0014] The *Streptococcus salivarius* MG-T313 provided by this invention was isolated from the oral cavity of healthy Chinese individuals. As a native symbiotic bacterium of the human oral cavity, it is safe in origin and naturally adapted to the oral microenvironment. It overcomes the shortcomings of existing technologies where exogenous probiotics such as *Lactobacillus* struggle to colonize the oral cavity. It possesses broad-spectrum antibacterial capabilities across bacterial species, forming significant inhibition zones against Gram-positive acid-producing cariogenic bacteria *Streptococcus mutans*, Gram-negative anaerobic periodontal pathogens *Fusobacterium nucleatum* subsp. *mucin* and *Porphyromonas gingivalis*, and the fungus *Candida albicans*. Furthermore, the diameter of the inhibition zones against *Streptococcus mutans*, *Candida albicans*, and *Fusobacterium nucleatum* subsp. *mucin* is significantly larger than that of the positive control strain *Streptococcus salivarius* K12. These characteristics allow it to be used simultaneously for caries prevention and treatment, periodontal inflammation control, halitosis improvement, and intervention for oral candidiasis. Furthermore, MG-T313 exhibits a 95.57% inhibition rate against biofilm formation by Streptococcus mutans, significantly superior to Streptococcus salivarius K12. It effectively disrupts the biofilm structure of cariogenic plaques and reduces their colonization and aggregation on the tooth surface, thereby lowering the risk of enamel demineralization and caries. Its adhesion rate to saliva-coated hydroxyapatite (simulating the acquired membrane on the oral tooth surface) reaches 62.50%, approximately 1.93 times that of Streptococcus salivarius K12 (32.38%), demonstrating excellent adhesion and colonization capabilities on the tooth surface. This is beneficial for maintaining an effective bacterial load and prolonging the duration of action under continuous saliva flushing and swallowing. After 24 hours of culture, MG-T313 achieves a self-aggregation rate of 85.65%, classifying it as a strain with strong self-aggregation capabilities, significantly superior to Streptococcus salivarius K12. This facilitates the formation of a stable beneficial bacterial biofilm in the oral cavity, resisting adverse external factors and achieving efficient colonization. Attached Figure Description
[0015] Figure 1 The diagram shows the diameter of the inhibition zone of Streptococcus salivarius MG-T313 against Streptococcus mutans in this invention (***p<0.001 compared with the positive strain group).
[0016] Figure 2 The diagram shows the diameter of the inhibition zone of Streptococcus salivarius MG-T313 against Candida albicans in this invention (*p<0.05 compared with the positive strain group).
[0017] Figure 3 The diagram shows the diameter of the inhibition zone of Streptococcus salivarius MG-T313 against Fusobacterium nucleatum in this invention (***p<0.001 compared with the positive strain group).
[0018] Figure 4 The diagram shows the diameter of the inhibition zone of Streptococcus salivarius MG-T313 against Fusobacterium nucleatum in this invention (***p<0.001 compared with the positive strain group).
[0019] Figure 5 The figure shows the biofilm inhibition rate of *Streptococcus salivarius* MG-T313 against *S. mutans* in this invention (****p<0.0001 compared with the positive strain group).
[0020] Figure 6 The figure shows the adhesion rate of *Streptococcus salivarius* MG-T313 to saliva-coated hydroxyapatite in this invention (****p<0.0001 compared with the positive strain group).
[0021] Figure 7 The results show the self-aggregation rate of Streptococcus salivarius MG-T313 in this invention (***p<0.001 compared with the positive strain group).
[0022] Figure 8 The results show the co-aggregation rate of Streptococcus salivarius MG-T313 and pathogenic bacteria in this invention (**p<0.01, ***p<0.001 compared with the positive strain group). Detailed Implementation
[0023] This application provides a Streptococcus salivarius MG-T313, with accession number CGMCC No.38628, accession date of 2026-05-11, deposited at the China General Microbiological Culture Collection Center (CGMCC), Institute of Microbiology, Chinese Academy of Sciences, Beijing.
[0024] In some specific embodiments, the *Streptococcus salivarius* MG-T313 comprises a DNA fragment with a nucleotide sequence as shown in SEQ ID NO.1.
[0025] In some specific embodiments, the *Streptococcus salivarius* MG-T313 contains a DNA fragment with a nucleotide sequence similarity of 50% or more to that shown in SEQ ID NO. 1. Specifically, the *Streptococcus salivarius* MG-T313 comprises a DNA fragment with a nucleotide sequence similarity of 50%, 55%, 60%, 65%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more to that of SEQ ID NO. 1. Preferably, the *Streptococcus salivarius* MG-T313 comprises a DNA fragment with a nucleotide sequence similarity of 90% or more to that of SEQ ID NO. 1; more preferably, the *Streptococcus salivarius* MG-T313 comprises a DNA fragment with a nucleotide sequence similarity of 99% or more to that of SEQ ID NO. 1. Specifically, the DNA fragment contained in the Streptococcus salivarius MG-T313 can be obtained by nucleotide substitution, deletion, insertion, or homologous recombination of nucleic acid fragments on the DNA chain with nucleotide sequences as shown in SEQ ID No. 1.
[0026] In some specific embodiments, the salicylic streptococcus MG-T313 is isolated from the oral cavity of a healthy human.
[0027] In some specific embodiments, the *Streptococcus salivarius* MG-T313 has inhibitory activity against one or more of the following microorganisms: *Listeria*, *Prevotella*, *Actinomyces*, *Klebsiella*, *Salmonella*, *Shigella*, *Streptococcus*, *Helicobacter*, *Staphylococcus*, *Porphyromonas*, *Clostridium*, *Fusobacterium*, *Bacillus*, *Candida*, or *Escherichia coli*; preferably, the microorganism is one or more of *Streptococcus mutans*, *Fusobacterium nucleatum* subsp. *proliferate*, *Porphyromonas gingivalis*, or *Candida albicans*. The inhibitory effect can be expressed as the size of the inhibition zone; that is, the better the inhibitory effect, the larger the area of the inhibition zone.
[0028] The present invention also provides a bacterial agent containing the aforementioned Streptococcus salivarius MG-T313.
[0029] In some specific embodiments, the aforementioned Streptococcus salivarius MG-T313 in the bacterial agent exists in one or more of the following forms: live bacteria, inactivated bacteria, fermentation products, or fermentation extracts. The fermentation products or fermentation extracts include fermentation broth, fermentation supernatant, cell-free extracts, or active metabolites.
[0030] In some specific embodiments, the microbial agent contains one or more of the following: Pediococcus pentosaceus, Lactobacillus paracasei, Lactobacillus helveticus, Lactobacillus acidophilus, Lactobacillus rhamnosus, Lactobacillus plantarum, Streptococcus thermophilus, Lactobacillus fermentum, Lactobacillus casei, Lactobacillus bulgaricus, Lactobacillus gasseri, Lactobacillus lactis, Lactobacillus reuteri, Lactobacillus salivarius, Lactobacillus fermentum, Bifidobacterium longum, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium animalis, Bifidobacterium bifidum, Bifidobacterium adolescentis, or Bifidobacterium lactis; preferably, the microbial agent contains Pediococcus pentosaceus, Lactobacillus paracasei, Lactobacillus rhamnosus, Lactobacillus plantarum, or Lactobacillus fermentum.
[0031] In some specific embodiments, the microbial agent further includes one or more of the following: prebiotics, vitamins, minerals, amino acids, polypeptides, emulsifiers, thickeners, sweeteners, flavorings, stabilizers, or preservatives.
[0032] Furthermore, the prebiotic may be selected from one or more of fructooligosaccharides, inulin, galactooligosaccharides, or polydextrose.
[0033] In some specific embodiments, the concentration of Streptococcus salivarius MG-T313 in the bacterial agent can be at least 1 × 10⁻⁶. 8 CFU / g, at least 2×10 8 CFU / g, at least 3×10 8 CFU / g, at least 4×10 8 CFU / g, at least 5×10 8 CFU / g, at least 6×10 8 CFU / g, at least 7×10 8 CFU / g, at least 8×10 8 CFU / g, at least 9×10 8 CFU / g, 1×10 9 CFU / g, at least 2×10 9 CFU / g, at least 3×10 9 CFU / g, at least 4×10 9 CFU / g, at least 5×10 9 CFU / g, at least 6×10 9 CFU / g, at least 7×10 9 CFU / g, at least 8×10 9 CFU / g, at least 9×10 9 CFU / g, at least 1×10 10 CFU / g, at least 2×10 10 CFU / g, at least 3×10 10 CFU / g, at least 4×10 10CFU / g, at least 5×10 10 CFU / g, at least 6×10 10 CFU / g, at least 7×10 10 CFU / g, at least 8×10 10 CFU / g, at least 9×10 10 CFU / g, or at least 1×10 11 CFU / g or higher.
[0034] In some specific embodiments, the microbial agent may be selected from one or more of the following forms: compressed candy, tablets, powders, granules, oral liquids, drops, gummies, capsules, jellies, solid beverages, or fermented dairy products.
[0035] The present invention also provides the use of the aforementioned Streptococcus salivarius MG-T313 or the aforementioned bacterial agent in the preparation of oral health improvement products, anti-allergy products or anti-inflammatory products.
[0036] In some specific embodiments, the oral health improvement product has one or more of the following functions: prevention, relief and / or treatment of dental caries; improvement of oral odor; regulation of the oral microecological environment; prevention, relief and / or treatment of periodontal disease; prevention, relief and / or treatment of gingival swelling and pain; reduction of dental plaque or tartar formation; prevention, relief and / or treatment of oral ulcers.
[0037] In some specific embodiments, the oral health improvement product, anti-allergy product, or anti-inflammatory product is a medicine, health product, or food.
[0038] When the product is a pharmaceutical product, it contains pharmaceutically acceptable excipients. Specifically, the excipients include various excipients and diluents that are not essential active ingredients and do not cause excessive toxicity after administration. The excipients include sterile water or physiological saline, stabilizers, excipients, antioxidants (ascorbic acid, etc.), buffers (phosphate, citric acid, other organic acids, etc.), preservatives, surfactants (PEG, Tween, etc.), chelating agents (EDTA, etc.), or binders. The excipients also contain other low molecular weight peptides, serum albumin, glycine, glutamine, asparagine, arginine, polysaccharides, monosaccharides, mannitol, or sorbitol. When the excipients are used in an aqueous solution for injection, they are selected from physiological saline, isotonic glucose solution, isotonic D-sorbitol solution, isotonic D-mannose solution, or isotonic D-mannitol or sugar alcohol solution. The aqueous solution for injection contains a solubilizer. The solubilizer is selected from alcohols (ethanol), polyols (propylene glycol or PEG) and / or nonionic surfactants (Tween 80 or HCO-50).
[0039] In this invention, the term "similarity" is defined as the percentage of identical nucleotide residues in a candidate nucleotide sequence to a reference nucleotide sequence after aligning nucleotide sequences (and, where necessary, introducing gaps) to obtain the maximum percentage sequence identity, without considering any conserved substitutions as part of the sequence identity. Sequence alignment can be performed using various methods in the art to determine the percentage nucleotide sequence similarity, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN, or MEGALIGN (DNASTAR) software. Those skilled in the art can determine suitable parameters for measuring the alignment, including any algorithm required to obtain the maximum alignment of the full length of the sequences being compared.
[0040] In this invention, the term "vitamin" refers to a class of trace organic substances that humans and animals must obtain from food to maintain normal physiological functions. Common examples may be selected from one or more of vitamin A, B vitamins, vitamin C, vitamin D, vitamin E, or vitamin K.
[0041] In this invention, the term "mineral" refers to an inorganic element essential to the human body, which often exists in the form of metal salts, such as calcium salts, phosphates, potassium salts, sodium salts, magnesium salts, iron salts, zinc salts, copper salts, iodates, or selenates.
[0042] In this invention, the term "probiotics" refers to live microorganisms that, when administered in adequate amounts, confer health benefits to the host, such as restoring or improving the composition of the gut microbiota. They are often provided as dietary supplements containing potentially beneficial bacteria or yeasts and are widely used in foods, including dairy products and probiotic-fortified foods.
[0043] The following specific examples illustrate the implementation of the present invention. Those skilled in the art can easily understand other advantages and effects of the present invention from the content disclosed in this specification. The present invention can also be implemented or applied through other different specific embodiments, and various details in this specification can also be modified or changed based on different viewpoints and applications without departing from the spirit of the present invention.
[0044] Before further describing specific embodiments of the present invention, it should be understood that the scope of protection of the present invention is not limited to the specific embodiments described below; it should also be understood that the terminology used in the embodiments of the present invention is for describing specific embodiments and not for limiting the scope of protection of the present invention; in the specification and claims of the present invention, unless otherwise expressly stated in the text, the singular forms "a", "an" and "this" include the plural forms.
[0045] When numerical ranges are given in the embodiments, it should be understood that, unless otherwise stated in the present invention, both endpoints of each numerical range and any value between the two endpoints may be selected. Unless otherwise defined, all technical and scientific terms used in this invention have the same meaning as commonly understood by one of ordinary skill in the art. In addition to the specific methods, apparatus, and materials used in the embodiments, based on the knowledge of the prior art possessed by one of ordinary skill in the art and the description of this invention, any prior art methods, apparatus, and materials similar to or equivalent to those described, apparatus, and materials in the embodiments of this invention may be used to implement the present invention.
[0046] The nucleotide sequence described in this application is as follows:
[0047] SEQ ID No.1
[0048]
[0049] Example 1: Inhibitory effect of Streptococcus salivarius MG-T313 on pathogenic bacteria
[0050] 1. Experimental strain
[0051] Target bacterium: Streptococcus salivarius MG-T313 (identified by 16S rDNA, the nucleotide sequence of which is shown in SEQ ID No. 1), isolated from the oral cavity of a healthy Chinese woman, and cryopreserved in glycerol tubes at -80°C. Under normal circumstances, colonies are obtained by inoculating the bacteria onto the surface of MRS solid agar plates and incubating them upside down at 37°C for 24-48 hours. Single colonies are then picked and inoculated into MRS liquid agar and incubated at 37°C for 18-24 hours to obtain the activated strain.
[0052] Pathogenic bacteria culture: Streptococcus mutans (GDMCC1.518) and Fusobacterium nucleatum subsp. polymorphum (GDMCC1.386): Take 200 μL of cryopreserved glycerol culture from both strains stored at -80℃ and, under aseptic conditions, inoculate each into a sterile test tube containing 10 mL of TSB medium. Incubate anaerobically at 37℃ for 16-20 h. Transfer the enriched cultures of both bacteria to sterile centrifuge tubes and centrifuge at 4000 r / min for 10 min. Adjust the viable count of both bacteria to 1.0 × 10⁻⁶ with sterile physiological saline. 6 CFU / mL, sealed and stored at 4℃ for later use. Candida albicans ATCC18804: Take a glycerol cryopreservation tube stored at -80℃, and inoculate 200µL of the cryopreserved bacterial solution into a test tube containing 10 mL of SD medium. Place the inoculated SD medium test tube in a 37℃ constant temperature shaker, set the rotation speed to 180 r / min, and incubate in an aerobic environment for 16-20 h. Transfer the enriched culture to a sterile centrifuge tube, centrifuge at 4000 r / min for 10 min, and adjust the viable count to 1.0 × 10⁻⁶ with sterile physiological saline. 6CFU / mL, sealed and stored at 4℃ for later use. *Porphyromonas gingivalis* bio-53046: Glycerol cryopreserved at -80℃ was plated on TSB blood agar plates for activation. The culture was then strictly anaerobic at 37℃ for 4-7 days. Single colonies were inoculated onto TSB medium and strictly anaerobic at 37℃ for 48-72 h. The enriched culture was transferred to sterile centrifuge tubes and centrifuged at 4000 r / min for 10 min. The viable count was adjusted to 1.0 × 10⁻⁶ with sterile physiological saline. 6 CFU / mL, sealed and stored at 4℃ for later use.
[0053] Culture medium preparation:
[0054] Preparation of MRS medium: Weigh 10.0 g tryptone, 10.0 g beef extract, 5.0 g yeast extract, 20.0 g glucose, 2.0 g diammonium citrate, 5.0 g sodium acetate, 0.58 g magnesium sulfate (7H2O), 0.25 g manganese sulfate (4H2O), 1.0 mL Tween-80, and 0.5 g L-cysteine. Dissolve in 1 L of distilled water, adjust the pH to 5.7 ± 0.2, and sterilize at 121℃ for 15 min. For MRS solid medium, an additional 20 g agar needs to be added.
[0055] SD medium: Weigh 10.0 g of an equal mixture of animal tissue pepsin hydrolysate and tryptone, and 20.0 g of glucose, dissolve in 1 L of distilled water, adjust the pH to 5.6±0.2, and sterilize at 121℃ for 15 min. SD solid medium requires the addition of 20 g of agar.
[0056] TSB medium: Weigh 17.0 g tryptone, 3.0 g soybean papain hydrolysate, 5.0 g sodium chloride, 2.5 g dipotassium hydrogen phosphate, 2.5 g glucose, 1.0 g yeast extract, 5.0 mg heme chloride, and 0.5 mg L-cysteine hydrochloride, and bring the volume to 1 L. Adjust the pH to 7.3±0.1 and sterilize at 121℃ for 15-20 min. After sterilization and cooling, add 1 mg vitamin K1. For TSB solid medium, an additional 20 g agar needs to be added.
[0057] TSB blood agar plates: Based on 1 L of modified TSB medium with 15 g agar added, mix well and sterilize at 121℃ for 15-20 min. After sterilization, wait until the temperature is about 55℃, add 1 mg vitamin K1 and 53 mL of defibrinated sheep blood, mix well and pour into plates, each plate containing 20-25 mL of medium.
[0058] 2 Experimental Methods
[0059] Preparation of bacterial suspension: Take the activated bacterial suspension of *Streptococcus salivarius* to be tested, first determine the viable count by plate counting method, and then adjust the bacterial suspension to 10⁻⁶. 8 CFU / mL;
[0060] Sterilize the SD / TSB solid culture medium and then cool it to about 55°C for later use. Sterilize disposable sterile culture dishes and Oxford cups, and place the sterilized Oxford cups into the disposable sterile culture dishes under aseptic conditions.
[0061] Add the pathogenic bacterial suspension to the SD / TSB solid medium cooled to about 55°C at an inoculation rate of 1%, mix quickly and gently (avoiding the formation of air bubbles), and then quickly pour the bacterial medium into sterile petri dishes with Oxford cups placed in them. The amount poured into each dish should be enough to cover the bottom of the petri dish with a uniform thickness (about 15-20 mL). Allow the medium to cool and solidify naturally.
[0062] Gently rotate the Oxford cup with sterile forceps to remove it, creating uniform wells. Use a sterile pipette to draw 100 μL of the test bacterial solution and accurately inject it into each well. A positive control group was also included, with 100 μL of typical oral probiotic strains of *Streptococcus salivarius*, *Streptococcus salivarius* K12 and *Streptococcus salivarius* M18, injected into each well. 1-7 During operation, avoid liquid overflowing from the cavity.
[0063] After adding the samples, gently cover the culture dishes. Place *Streptococcus mutans*, *Fusobacterium nucleatum* subsp. *mucinosa*, and *Porphyromonas gingivalis* in the anaerobic chamber, and place *Candida albicans* in the ordinary culture medium. Incubate at 37°C for the appropriate time.
[0064] Data recording: After the culture is completed, remove the petri dish and use a vernier caliper to measure the diameter of the inhibition zone around each well (referring to the entire diameter of the circular transparent zone). Each sample should be measured at least 3 times. Record the measurement data and calculate the average value (retain 2 decimal places).
[0065] 3. Experimental Results and Explanation
[0066] The results are as follows Figure 1-4As shown, MG-T313 exhibits antibacterial activity against *Streptococcus mutans*, *Fusobacterium nucleatum* subsp. *protozoa*, *Candida albicans*, and *Porphyromonas gingivalis* (forming a clear inhibition zone). Compared with the positive controls *Streptococcus salivarius* K12 and *Streptococcus salivarius* M18, MG-T313 showed significantly larger inhibition zones against these three pathogenic bacteria (*Streptococcus mutans* group, *Candida albicans* group, *Fusobacterium nucleatum* subsp. *protozoa* group, and *Fusobacterium nucleatum* subsp. *protozoa* group). This indicates that the antibacterial activity of *Streptococcus salivarius* MG-T313 against *Streptococcus mutans*, *Fusobacterium nucleatum* subsp. *protozoa*, and *Candida albicans* is stronger than that of *Streptococcus salivarius* K12 and *Streptococcus salivarius* M18. Furthermore, the antibacterial activity of *Streptococcus salivarius* MG-T313 against *Porphyromonas gingivalis* is also stronger than that of *Streptococcus salivarius* K12.
[0067] Example 2: Inhibitory effect of Streptococcus salivarius MG-T313 on biofilm formation of Streptococcus mutans
[0068] 1. Experimental Objective
[0069] In this embodiment, the inhibitory effect of salivarius MG-T313 on biofilm formation of Streptococcus mutans was evaluated.
[0070] 2 Experimental Methods
[0071] Adjust the S. mutans GDMCC1.518 suspension to a final concentration of 1×10⁻⁶. 5 CFU / mL, adjust the MG-T313 suspension of *Streptococcus salivarius* to a final concentration of 1×10⁻⁶. 6 CFU / mL was prepared for use. Three groups were set up in the 96-well plate: a blank control, a *S. mutans* GDMCC1.518 control group, and a *S. mutans* GDMCC1.518 + probiotic experimental group. Each group consisted of 100 µL of bacterial suspension (or culture medium) + 100 µL of the corresponding bacterial suspension, with 3 parallel wells. After anaerobic incubation at 37℃ for 24 h, the supernatant was discarded. The plate was gently washed twice with 300 µL PBS to remove airborne bacteria. 200 µL of 99% methanol was added for fixation at room temperature for 15 min, then discarded. 200 µL of 0.1% crystal violet was added and incubated at room temperature for 30 min. After discarding the staining solution, the plate was washed twice with 300 µL physiological saline, air-dried in a fume hood for 5 min, and finally dissolved in 200 µL of 33% acetic acid at room temperature for 30 min. The OD value was measured at 570 nm using a microplate reader. The biofilm inhibition rate was calculated using the formula: OD 570 Actual value to be measured = OD 570 Detection of OD 570 Culture medium control, inhibition rate (%) = [1 - (OD200)] 570 Actual / OD under test 570[S. mutans control group] × 100%
[0072] 3. Experimental Results and Explanation
[0073] like Figure 5 As shown, biofilm formation in the MG-T313 treatment group was significantly inhibited, with an inhibition rate of 95.57%, which was significantly higher than that in the positive control group of Streptococcus salivarius K12. This indicates that MG-T313 has a significant advantage in intervening in the biofilm formation of S. mutans, effectively destroying the biofilm structure of pathogenic S. mutans, reducing its colonization and accumulation on the tooth surface, and lowering the risk of dental caries.
[0074] Example 3: Test of the adhesion ability of *Streptococcus saliva* MG-T313 to saliva-coated hydroxyapatite
[0075] 1. Experimental Objective
[0076] In this embodiment, the OD of the supernatant after the adhesion experiment was detected. 600 The adhesion rate is calculated to reflect the adhesion characteristics of probiotics.
[0077] 2 Experimental Methods
[0078] Lactic acid bacteria treatment: Activated suspensions of Streptococcus salivarius MG-T313 and Streptococcus salivarius K12 were serially diluted using MRS medium to a final concentration of 1×10⁻⁶ for both strains. 9 CFU / mL, for later use.
[0079] Preparation of saliva-coated hydroxyapatite: 50 mg of hydroxyapatite was suspended in 10 mL of 0.2 mol / L NaOH solution and allowed to stand for 10 min to remove surface-active particles. This process was repeated three times or more. The precipitate was then washed with pure water until the pH of the supernatant was close to 7.0. The hydroxyapatite was allowed to precipitate naturally, and the supernatant was discarded. The precipitate was dried overnight at 80°C. The precipitate was coated with saliva at a ratio of 1 mg hydroxyapatite to 200 μL saliva, incubated at 37°C for 60 min, and then centrifuged at 2000 r / min for 5 min. The supernatant was discarded, and the resulting precipitate was the fully coated hydroxyapatite. It was resuspended in 20 times its weight of physiological saline for later use.
[0080] Adhesion assay: In a 24-well plate, 1 mL of the bacterial suspension to be tested and 100 μL of saliva-coated hydroxyapatite were added to each well. After thorough mixing, the plate was incubated at 37 ℃ on a shaker (180 r / min) for 60 min. After removal, the plate was allowed to stand for 5 min, and the supernatant was collected to measure its OD value. 600 value.
[0081] Data processing: Adhesion rate calculation formula: Adhesion rate % = (1 - Supernatant OD) 600 Value / Initial OD 600 Value) × 100%
[0082] 3. Experimental Results and Explanation
[0083] Experimental results are as follows Figure 6 As shown, the adhesion rate of *Streptococcus salivarius* MG-T313 to saliva-coated hydroxyapatite was significantly higher than that of *Streptococcus salivarius* K12: the adhesion rate of *Streptococcus salivarius* K12 was approximately 32.38%, while that of *S. salivarius* MG-T313 was approximately 62.50%; there was a significant difference between the two groups (***, usually indicating p < 0.001). This indicates that the adhesion ability of *Streptococcus salivarius* MG-T313 is significantly better than that of K12, and it may be more likely to colonize in scenarios involving adhesion and colonization, such as the oral cavity, and thus may more fully exert the efficacy of probiotics.
[0084] Example 4: Self-aggregation of Streptococcus salivarius MG-T313 and co-aggregation of probiotics against pathogenic bacteria.
[0085] 1. Experimental Objective
[0086] In this embodiment, the self-aggregation of Streptococcus salivarius MG-T313 and its co-aggregation effect on pathogenic bacteria were detected.
[0087] 2 Experimental Methods
[0088] Adjust the OD values of pathogenic bacteria suspension and probiotic suspension to OD values respectively. 600 0.5±0.05 was reserved. Self-aggregation assay: The probiotic suspension to be tested was cultured anaerobicly or aerobically at 37℃. At 0 h, 2 h, 4 h, 6 h, and 24 h of culture, the supernatant was collected, and its OD value was measured. 600 The self-aggregation rate (%) is calculated according to the formula: = [(A0-A...] t [A0]×100% (where A0 is the OD of the initial bacterial suspension) 600 Value, A t OD of the supernatant after culture time t 600 Coagulation assay: Probiotic suspension and pathogenic bacterial suspension were mixed in equal volumes and cultured anaerobically or aerobically at 37°C. After 24 h of culture, the supernatant was collected and its OD value was measured. 600 The co-aggregation rate (%) is calculated according to the formula: = [(A0 + A...]] p -A m ) / (A0+A p []×100% (where A0 is the initial OD of the probiotic suspension) 600 Value, A p Initial OD of pathogenic bacterial suspension600 Value, A m OD of the supernatant after mixed culture time t 600 The coagulation rate is calculated using the value.
[0089] Data processing: Adhesion rate calculation formula: Adhesion rate % = (1 - Supernatant OD) 600 Value / Initial OD 600 Value) × 100%
[0090] 3. Experimental Results and Explanation
[0091] Based on the differences in the self-aggregation rate of strains, their self-aggregation ability can be divided into three levels: weak self-aggregation ability (16%–35%), moderate self-aggregation ability (35%–50%), and strong self-aggregation ability (>50%). Figure 7 It can be seen that after 24 h of culture, the self-aggregation rate of MG-T92 is greater than 50%, reaching 85.65%, indicating that MG-T313 has a strong self-aggregation ability and the potential to form a stable biofilm in the oral cavity and achieve efficient colonization, which is superior to positive strains.
[0092] Figure 8 The results of co-aggregation rate determination of MG-T313 against four oral pathogenic bacteria were presented. The results showed that both probiotic strains exhibited high co-aggregation activity (over 80%) against *S. mutans* GDMCC1.518, *F. nucleatum subsp. polymorphum* GDMCC1.386, *C. albicans* ATCC18804, and *P. gingivalis* bio-53046, but MG-T313 was significantly superior to the positive strain. In conclusion, MG-T313 possesses excellent self-aggregation and co-aggregation capabilities, laying a solid foundation for its colonization in the oral microecology and its antibacterial regulatory effects.
[0093] 1.Reichardt, Elisabeth et al. "Antimicrobial effect of probioticbacteriocins on Streptococcus mutans biofilm in a dynamic oral flow chambermodel - an in vitro study." Journal of oral microbiology vol. 16,1 2304971.28 Jan. 2024, doi:10.1080 / 20002297.2024.2304971
[0094] 2.Poorni, Saravanan et al. “Effect of Probiotic Streptococcussalivarius K12 and M18 Lozenges on the Cariogram Parameters of Patients WithHigh Caries Risk: A Randomised Control Trial.” Cureus vol. 14,3 e23282. 18Mar. 2022, doi:10.7759 / cureus.23282
[0095] 3.Nilchian, Firoozeh et al. “Evaluation of the effects ofStreptococcus salivarius M18 and K12 probiotic bacteria on the Streptococcusmutans in saliva: A randomized clinical trial.” Dental research journal vol.21 39. 12 Jul. 2024
[0096] 4.Yoo, Hyun-Jun et al. “Inhibitory effect of Streptococcus salivariusK12 and M18 on halitosis in vitro.” Clinical and experimental dental researchvol. 6,2 (2020): 207-214. doi:10.1002 / cre2.269
[0097] 5.Kim, Hye-Ji, and Hyun-Jun Yoo. “Inhibitory effects of Streptococcussalivarius K12 on formation of cariogenic biofilm.”Journal of dental sciencesvol. 18,1 (2023): 65-72. doi:10.1016 / j.jds.2022.07.011
[0098] 6.Park, Ji-A et al. "Oral Probiotics, Streptococcus salivarius K12and M18, Suppress the Release of Volatile Sulfur Compounds and a VirulentProtease from Oral Bacteria: An In-Vitro Study." Oral 7.Wang, Yan et al. "Probiotic Streptococcus salivarius K12 Alleviates Radiation-Induced OralMucositis in Mice." Frontiers in immunology vol. 12 684824. 4 Jun. 2021, doi:10.3389 / fimmu.2021.684824health & preventive dentistry vol. 21 259-270. 29Aug. 2023, doi:10.3290 / j.ohpd.b4328987
[0099] The above embodiments are for illustrating the implementation schemes disclosed in this invention and should not be construed as limiting the invention. Furthermore, various modifications and variations of the methods listed herein will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been specifically described in conjunction with various specific preferred embodiments, it should be understood that the invention should not be limited to these specific embodiments. In fact, various modifications as described above that are obvious to those skilled in the art to obtain the invention should be included within the scope of this invention.
Claims
1. A Streptococcus salivarius MG-T313, characterized in that, The accession number of the Streptococcus salivarius MG-T313 is CGMCC No.38628.
2. The Streptococcus salivarius MG-T313 according to claim 1, characterized in that, The Streptococcus salivarius MG-T313 contains a DNA fragment with a nucleotide sequence as shown in SEQ ID NO.
1.
3. The Streptococcus salivarius MG-T313 according to claim 1, characterized in that, The Streptococcus salivarius MG-T313 strain exhibits inhibitory activity against one or more of the following microorganisms: Listeria, Prevotella, Actinomyces, Klebsiella, Salmonella, Shigella, Streptococcus, Helicobacter, Staphylococcus, Porphyromonas, Clostridium, Fusobacterium, Bacillus, Candida, or Escherichia coli; preferably, the microorganism is one or more of Streptococcus mutans, Fusobacterium nucleatum subsp. Proteus, Porphyromonas gingivalis, or Candida albicans.
4. A microbial agent, characterized in that, The bacterial agent contains any one of the Streptococcus salivarius MG-T313 as described in claims 1-3.
5. The microbial agent according to claim 4, characterized in that, The microbial agent contains one or more of the following: Pediococcus pentosaceus, Lactobacillus paracasei, Lactobacillus helveticus, Lactobacillus acidophilus, Lactobacillus rhamnosus, Lactobacillus plantarum, Streptococcus thermophilus, Lactobacillus fermentum, Lactobacillus casei, Lactobacillus bulgaricus, Lactobacillus gasseri, Lactobacillus reuteri, Lactobacillus fermentum, Lactobacillus salivarius, Bifidobacterium longum, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium animalis, Bifidobacterium bifidum, Bifidobacterium adolescentis, or Bifidobacterium lactis; preferably, the microbial agent contains Pediococcus pentosaceus, Lactobacillus paracasei, Lactobacillus fermentum, Lactobacillus plantarum, or Lactobacillus rhamnosus.
6. The microbial agent according to claim 4, characterized in that, The microbial agent also contains one or more of the following: prebiotics, vitamins, minerals, amino acids, polypeptides, emulsifiers, thickeners, sweeteners, flavorings, stabilizers, or preservatives.
7. The microbial agent according to claim 4, characterized in that, The concentration of Streptococcus salivarius MG-T313 in the bacterial agent is at least 1 × 10⁻⁶. 8 CFU / g, at least 2×10 8 CFU / g, at least 3×10 8 CFU / g, at least 4×10 8 CFU / g, at least 5×10 8 CFU / g, at least 6×10 8 CFU / g, at least 7×10 8 CFU / g, at least 8×10 8 CFU / g, at least 9×10 8 CFU / g, 1×10 9 CFU / g, at least 2×10 9 CFU / g, at least 3×10 9 CFU / g, at least 4×10 9 CFU / g, at least 5×10 9 CFU / g, at least 6×10 9 CFU / g, at least 7×10 9 CFU / g, at least 8×10 9 CFU / g, at least 9×10 9 CFU / g, at least 1×10 10 CFU / g, at least 2×10 10 CFU / g, at least 3×10 10 CFU / g, at least 4×10 10 CFU / g, at least 5×10 10 CFU / g, at least 6×10 10 CFU / g, at least 7×10 10 CFU / g, at least 8×10 10 CFU / g, at least 9×10 10 CFU / g, or at least 1×10 11 CFU / g or higher.
8. The microbial agent according to claim 4, characterized in that, The microbial agent is selected from one or more of the following: compressed candy, tablets, powders, granules, powders, oral liquids, drops, soft candy, capsules, jellies, solid beverages, or fermented dairy products.
9. Use of the Streptococcus salivarius MG-T313 as described in any one of claims 1-3 or the bacterial agent as described in any one of claims 4-8 in the preparation of products for improving oral health, anti-allergy products or anti-inflammatory products.
10. The use according to claim 9, characterized in that, The oral health improvement product has one or more of the following functions: prevention, relief and / or treatment of dental caries; improvement of breath odor; regulation of the oral microecological environment; prevention, relief and / or treatment of periodontal disease; prevention, relief and / or treatment of gingival swelling and pain; reduction of dental plaque or tartar formation; prevention, relief and / or treatment of oral ulcers; preferably, the oral health improvement product, anti-allergy product or anti-inflammatory product is a food, health product or drug; preferably, the product also contains excipients acceptable in food, health product or drug.
